raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting. Study design Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Different definitions of virological failure (VF) and treatment failure (TF) were employed. Kaplan-Meier curves and Cox regression models were performed to estimate time to event probability. Results We included 72 HIV-infected patients, 22 (31%) of these were female, 31 (43%) men who have sex with men (MSM) amd 15 (21%) had hepatitis co-infections. Median age was 44 (IQR: 35-50) years amd CD4 count was 389 (IQR 283-606) cells/mmc. Median follow-up time for TF was 24 (IQR 9-31) months. Twenty-five discontinuations occurred (60% simplifications); only 2 (8%) were toxicity-driven (lipid elevations). The probability of VF (confirmed VL >50 copies/mL) was estimated at 7% [95% confidence interval (CI) 1-13%] by 12 and 9% (95% CI 2-16%) by 24 months. When considering TF, we found a probability of stop/intensification/single VL > 200 copies/ mL of 13% (95% CI 1-17%) and 22% (95% CI 11-33%) by 12 and 24 months. Female gender (adjusted relative hazard, ARH = 0.10; 95% CI 0.01-0.74; p = 0.024) and older age (AHR = 0.50 per 10 years older; 95% CI 0.25-0.99; p = 0.045) were associated with a lower risk of TF. A previous PI failure was strongly associated with TF (AHR = 52.6, 95% CI 3.6-779; p = 0.004). Conclusions DRV/r + RAL is a valuable NRTI-sparing option, especially in female and older patients, with a relatively low risk of VF and good tolerability after 2 years since start in an ART-experienced population. However, previous PI-failure should be a limiting factor for this strategy.
Keywords Darunavir/ritonavir · Raltegravir · Efficacy · Tolerability · Antiretroviral therapy · NRTI-sparing regimen Background Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy (cART) [1] [2] [3] . Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing or single NRTIincluding regimens [4] [5] [6] . In a recent study conducted in patients receiving a successful multidrug salvage regimen with at least two active drugs including a boosted protease inhibitor (PI), the withdrawal of NRTI was safe [7] . Two NRTI plus a third drug, a PI, an integrase inhibitor (INI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) still represent the cornerstone for cART initiation in naïve patients, and the International and National treatment Guidelines do not recommended NRTI-sparing regimens in the first-line [8] [9] [10] [11] .
Although most studies were conducted in the scenario of antiretroviral-naïve patients, in clinical practice, this NRTIsparing regimen is being employed in different strategies (salvage, simplification, switching). Other studies suggest that the combination is indeed widely used, at least in Spain and Italy [7, [12] [13] [14] . A recent study by Calza et al. showed that in 82 virologically suppressed patients without history of PI failure the combination of RAL + DRV/r was capable of maintaining a virologic success in more than 92.7% of cases at 48 weeks with a significant improvement of lipid profile and reduction of tubular proteinuria [15] .
Objectives
In this analysis, we aimed to investigate the risk of virological failure (VF), and tolerability of switching to DRV/r plus RAL while having a viral load (VL) ≤50 copies/mL in an unselected population from the real life setting.
Study design
Treatment experienced HIV-1-infected patients enrolled in the ICONA (Italian Cohort Naïve Antiretrovirals) Foundation Study cohort were included in this analysis if they switched their current regimen to DRV/r + RAL with an HIV-RNA ≤ 50 copies/mL (baseline). No patient had previous exposure to integrase inhibitors. Virological failure (VF) was defined as a confirmed HIV-RNA >50 copies/ mL (two consecutive values). We also investigated the risk of treatment failure (TF) defined as single HIV-RNA >200 copies/mL, intensification or discontinuation of DRV/r + RAL for any reason. Glomerular filtration rate was estimated using the CKD-EPI formula [16] . A range of methods were used to measure HIV-RNA according to availability at the participating sites. The most frequent were Real time Abbot PCR (n = 10, 13%), NASBA (n = 4, 6%) and Roche (n = 3, 4%).
We performed time to event estimates using KaplanMeier curves and Cox regression models. Covariates in the final model included the number of failures on regimens containing a PI, gender, mode of HIV transmission, HBV/ HCV co-infection, calendar year of switch, age, CD4 nadir count, CD4 count at cART initiation, viral load at cART initiation and duration of viral suppression <50 copies/mL.
Results
Seventy-two patients were included: 22 (31%) female, 31 (43%) MSM, 15 (21%) had hepatitis co-infections (10 with HCV and 5 with HBV). Median baseline characteristics were age 44 [Interquartile range (IQR) 35-50] years, CD4 cell count was 389/mmc (IQR 283-606); HIV-RNA at initiation of cART was 4.22 (IQR 2.92, 6.54) log 10 copies/mL and total median duration of HIV-RNA ≤50 copies/ mL 5 months (IQR 1-53). Time from initiation of previous ART was 3 (IQR 1-30) months and median time from first starting antiretrovirals to the switch to DRV/r + RAL was 10 months (IQR 1-109). Seventy-four (88.9%) patients were receiving a boosted PI at baseline and 14 (19%) patients previously failed virologically a PI-based cART before baseline. On average participants have been previously exposed to two lines of treatment (IQR 1-5), for 65% the dual regimen was the 4th therapy started. Forty-eight of the 72 patients (67%) were already receiving darunavir/r prior to switching to the dual regimen. Thirty-one (43%) patients switched from a 2 NRTI-including triple cART, 35 (49%) from a PI monotherapy, 3 (4%) from a NRTI + PI/r regimen and 3 (4%) from other NRTI-including regimens.
Median total cholesterol levels were 180 (IQR 155-224) mg/dl, HDL 45 (IQR 35-54) mg/dl and triglycerides 106 (IQR 75-156) mg/dl. Complete baseline patients characteristics are shown in Table 1 . The median follow-up time for the composite endpoint was 24 (IQR 9-31) months. The median follow-up time by gender was 24.5 months (IQR 12-31) in males and 17.5 (5-33) in females. The proportion of people with at least 24 months of follow-up was 27/50 (54%) among males and 10/22 (45%) among females.
Overall, we observed 30 discontinuation events of the dual regimen. However, regimen simplification in terms of pill burden was the most frequent cause of discontinuation and occurred in 15 out of 30 patients (50%), 14 of whom 1 3 discontinued RAL, whereas toxicity-driven interruption occurred only in 3 (10%) cases (1 lipid elevation, 1 renal and 1 central nervous system toxicity). The remaining causes of discontinuations included patients' decision in 2 (7%) and drugdrug interactions, compliance with guidelines, virological failure, immunological failure, regimen intensification, death, temporary stop (physician's decision) in 1 (3%) case each. In 2 (7%) patients the cause of discontinuation was unknown. Table 2 shows the number of patients experiencing VF and TF and the Kaplan-Meier estimates by 12 and 24 months, respectively, for each of the adopted endpoints. The probability of VF defined as confirmed VL >50 copies/mL was 7% [95% confidence interval (CI) 1-13%] by 12 months and 9% (95% CI 2-16%) by 24 months. When considering the composite endpoint of TF we found a probability of stop/intensification and single value of VL >200 copies/mL of 13% (95% CI 1-17%) and 22% (95% CI 11-33%) by 12 and 24 months, respectively.
Still considering the composite TF endpoint defined as stop/intensification and single value of VL >200 copies/ Time from initiation of previous cART, years 1 (1, 29) mL, from fitting a multivariable Cox regression analysis, female gender (adjusted relative hazard, ARH = 0.10; 95% CI 0.01, 0.74, p = 0.024) and older age (AHR = 0.50 per 10 years older; 95% CI 0.25-0.99, p = 0.045) were associated with a lower risk of TF. Having previously experienced virological failure to a PI-based regimen was the strongest predictor of failure of the dual strategy (AHR = 52.6, 95% CI 3.6-779, p = 0.004). In contrast, viral load at starting cART, CD4 cell nadir and hepatitis coinfections were not associated with increased risk of TF (Table 3) . Historical genotypes were available for 47/72 (65%) patients. When looking at the virological endpoint of time to a single VL >200 copies (part of the composite outcome) those with major IAS PI resistance mutations (2/5, 40%) showed a higher risk of failure compared to those without (8/34, 19%) but the difference was not statistically significant (Chi square p = 0.28). The univariate Hazard ratio (HR) for failure from fitting a univariable Cox regression model was 2.12 (95% CI 0.80-5.66, p = 0.13) for those with PI resistance vs. no PI resistance detected.
When looking at the endpoint of confirmed VL >50 copies/ml results were similar with patients with major PI resistance mutations (2/5, 40%) showing an increased risk of failure compared to those without (6/42, 14%, p = 0.15). With regards to tolerability, we did not find any significant modification of total cholesterol, high-density lipoproteins (HDL), triglycerides, eGFR and alanine transaminase (AST) levels over 24 months (Fig. 1) .
Discussion
Current guidelines suggest the use of a combination of three antiretroviral drugs as initial therapy, including 2 NRTIs plus 1 PI/r, 1 integrase inhibitor or 1 NNRTI [8] [9] [10] [11] . However, taking into account the rising evidence of nucleoside analogues long-term toxicity, NRTI-sparing strategies are being used in clinical practice.
We showed that, in an unselected patient population, representative of the clinical practice setting in Italy, a dual therapy including DRV/r + RAL seems to be moderately effective and tolerated over an average follow-up of 2 years. We found a relatively low probability of VF (considering both confirmed VL >50 or single value of VL >200 copies/mL) ranging between 9 and 15% by 24 months from the time of switch. When we compared our results with those of the study by Calza et al. in a similar patient population we found higher rates of pure virological failure at 48 weeks (7 vs 2.4%). However, it should be considered that in the study by Calza et al. patients with previous failure to PI containing regimens were excluded thus probably explaining the observed difference [15] .
When considering the composite outcome of TF we observed a probability of 13 and 22% of failure at 12 and 24 months for the conservative definition of a single value of VL >200 copies/mL and stop/intensification. This result is in line with previous observational data on triple therapy in the observational cohort studies [17, 18] .
Female gender and older age were independently associated with significantly lower risk of TF. It is possible that at least older age could represent a marker of better adherence [19, 20] .
Contrary to what was found in PI/r monotherapy studies [ patients with shorter duration of viral suppression, low nadir CD4 and with hepatic co-infections, suggesting that DRV/r + RAL might be used safely by a larger proportion of individuals. Having previously failed a PI-based regimen was strongly associated with TF. Furthermore, we showed that the presence of major IAS PI resistance was associated with an increased HR of virological failure, especially when considering a confirmed VL >50 copies/mL. Therefore, a previous failure of a PI-based regimen, especially if major IAS PI resistance mutations are detected, should remain a main limiting factor when selecting people for this strategy.
Our results also suggest that RAL + DRV/r is generally safe with a probability of discontinuation due to adverse events of 10% by 2 years.
We showed no significant modification in lipid profile whereas Calza et al. evidenced a significant reduction in triglyceride levels after 48 weeks [15] . However, in that study, baseline mean triglyceride values were above the normal range (286 mg/dL) compared to our patients that showed a median of 106 (IQR 75-156) mg/dl. Since our patients started from normal levels no further benefit was expected and our data suggest that the combination of DRV + RAL was not associated with a worsening in lipid profile.
Our results also showed a non-significant modification of eGFR during 24 months of follow-up as also suggested by Calza et al. and highlight the renal tolerability of the combination [15] .
Our data also showed a trend to increase in CD4 cell count over time which is in line with the significant increase shown by Calza et al. at 48 weeks [15] . However, since only a few patients had available data at each followup time, we think it is fair to say that bigger studies are needed to confirm this result.
Most regimen discontinuations were due to treatment simplification (15, 50%) and twice daily RAL was the drug stopped probably due to the fear of selected nonadherence to one of the two daily doses. However, only a minority of discontinuations was due to virological failure (1, 3%) and toxicity (3, 10%) over 2 years. Adherence is a complex phenomenon that implies acceptance of the diagnosis and motivation to carry out the treatment, possession of appropriate skills and the ability to overcome any difficulties that appear to maintain the level of treatment success over time. In patients with multiple previous cART regimen tolerability may favor adherence more than the daily schedule. Although once daily dose is the goal to improve adherence, it is not always superior to twice daily dosing in terms of virologic success. In fact Nachega et al. evidenced that once daily therapy is associated with better adherence but not with better virologic results in a systematic review of 19 clinical trials [23] . Another recent study by Arroyo et al. found no difference in adherence rates in patients receiving once or twice daily regimens [24] . A French study showed that nonadherence was independently associated with side effects, and having a three times or more daily dosing regimen in comparison to once or twice daily therapy [25] .
The upcoming availability of 1200 mg once daily RAL and the present possibility to use co-formulated DRV/Cobicistat could represent a future advantage of the combination of DRV + RAL in virologically suppressed patients.
The main limitation of our analysis is the lack of a control group to compare the failure estimates of the dual DRV/r + RAL regimen to that of a standard triple cART. In particular, it is not obvious to set a threshold below which the proportion of failure of this strategy is too high to be acceptable (compared to remaining on triple regimens for example). In this case even the historical controls are not fully comparable as performed in the context of first-line cART. Furthermore, since only a half of the patients were switched from NRTI-including cART to DRV/r + RAL, this study cannot evaluate the potential advantages of switching from a NRTI-including to a dual NRTI-sparing regimen.
In conclusion, switching to DRV/r + RAL in clinical practice is a valuable NRTI-sparing regimen, with a relative low risk of VF (7-9%) and good tolerability after 2 years since start in an antiretroviral-experienced population. Of note, female and older patients, both vulnerable populations, seem to have greater benefits from this strategy. Larger studies are needed to establish more solid criteria for selecting people who might benefit from this dual regimen but previous failure of a PI-based ART should represent a limiting factor for this strategy. Authors' contributions GM, SR, ACL, ADB and AA contributed to study conception and design, analysis and interpretation of the data and drafting of the article; SDG, SB, ADL, AC and NG contributed to the analysis and interpretation of data and to the critical revision of the manuscript for important intellectual content; all authors gave final approval of the final manuscript.
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